The Yale Diabetes Research Center (DRC) was established in 1993 with the goal of promoting research in diabetes and related metabolic and endocrine disorders at the University. The DRC brings together a multidisciplinary group of over 100 member and associate member scientists as well as professional supporting staff, new investigators and research trainees from in many departments and 4 colleges or schools at Yale University The scope of the research activities of the membership is very broad, ranging from basic molecular and cellular biology to whole body physiology and the treatment of diabetic patients. DRC members, however, share a common interest in research focused on diabetes or related metabolic disorders or that is fundamental to the understanding of its pathogenesis or for the development of new diabetes treatment strategies. The design of the Yale DRC is aimed at developing an infrastructure that could serve as a catalyst to achieve these goals. The cornerstone of the DRC is its five Research Cores that provide funded basic and clinical investigators with the opportunity to more efficiently utilize resources and expand the scope of their research programs. The Clinical Metabolism and the Diabetes Translational Cores facilitate metabolic research in patients, whereas the Molecular Genetic Mouse Core, Physiology and Cell Biology Cores that comprise the more basic science focus of the Center offer investigators the tools to create and test novel animal models starting from the molecule and ending with biological outcomes. The Administrative Core oversees the operation of the Center, its Pilot/Feasibility Project and Enrichment Programs, and helps to coordinate patient-based research in diabetes. The goals of the DRC are to: 1) stimulate multidisciplinary interactions, particularly between basic and clinical scientists; 2) encourage established investigators not presently working in diabetes-related areas, to bring their expertise to bear on problems relevant to diabetes; 3) efficiently organize tim e consuming and/or costly techniques through Core facilities to enhance the productivity of investigators conducting research in diabetes related areas; 4) promote new research programs through pilot feasibility projects; 5) enhance the quality of diabetes research training, and 6) create a stimulating institutional environment that expands research efforts of its members to achieve new strategies to prevent and treat diabetes at the local, and ultimately at the national level.

Public Health Relevance

The Yale Diabetes Research Center provides the scientific infrastructure to support a wide spectrum of clinical and basic scientists who are working to better understand the factors driving the development of diabetes and to facilitate the translation of discoveries from the bench to the bedside that lead to new strategies for the treatment of individuals with, or who are at risk for developing diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK045735-27
Application #
9657006
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Hyde, James F
Project Start
1997-01-01
Project End
2023-01-31
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
27
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Goedeke, Leigh; Bates, Jamie; Vatner, Daniel F et al. (2018) Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents. Hepatology 68:2197-2211
Sherr, Jennifer L (2018) Closing the Loop on Managing Youth With Type 1 Diabetes: Children Are Not Just Small Adults. Diabetes Care 41:1572-1578
Gassaway, Brandon M; Petersen, Max C; Surovtseva, Yulia V et al. (2018) PKC? contributes to lipid-induced insulin resistance through cross talk with p70S6K and through previously unknown regulators of insulin signaling. Proc Natl Acad Sci U S A 115:E8996-E9005
RISE Consortium (2018) Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test. Diabetes Care 41:1707-1716
RISE Consortium (2018) Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. Diabetes Care 41:1696-1706
Gülden, Elke; Chao, Chen; Tai, Ningwen et al. (2018) TRIF deficiency protects non-obese diabetic mice from type 1 diabetes by modulating the gut microbiota and dendritic cells. J Autoimmun 93:57-65
Corbit, Kevin C; Camporez, João Paulo G; Edmunds, Lia R et al. (2018) Adipocyte JAK2 Regulates Hepatic Insulin Sensitivity Independently of Body Composition, Liver Lipid Content, and Hepatic Insulin Signaling. Diabetes 67:208-221
Habtemichael, Estifanos N; Li, Don T; Alcázar-Román, Abel et al. (2018) Usp25m protease regulates ubiquitin-like processing of TUG proteins to control GLUT4 glucose transporter translocation in adipocytes. J Biol Chem 293:10466-10486
Perry, Rachel J; Peng, Liang; Cline, Gary W et al. (2018) Mechanisms by which a Very-Low-Calorie Diet Reverses Hyperglycemia in a Rat Model of Type 2 Diabetes. Cell Metab 27:210-217.e3
Xu, Ke; Zhang, Xinyu; Wang, Zuoheng et al. (2018) Epigenome-wide association analysis revealed that SOCS3 methylation influences the effect of cumulative stress on obesity. Biol Psychol 131:63-71

Showing the most recent 10 out of 620 publications